Our Privacy Statment & Cookie Policy

All LSEG websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

December 14, 2020

News in Charts: Will the US recovery falter, as COVID case numbers soar?

by Fathom Consulting.

The US is drawing up policy plans for a relief stimulus package to help its economy through the remaining months of the pandemic. COVID-19 cases are rising sharply once more in the US, and with other major western economies starting their vaccination programmes, the US is facing a key period for getting both its economic and its health programmes in order – challenges that are closely interlinked.

Net non-farm US payrolls in November pointed to an increase of 245,000 people in employment. That marked a slowdown from October’s 610,000 increase, but suggested some resilience in the economy despite a sharp increase in coronavirus infections through the month. It seems likely however that December’s jobs report will show a drop in US employment, as surging infections lead to increased economic restrictions in some states. The California governor, Gavin Newsom, announced on 3 December that stay-at-home orders would automatically be triggered when regions fell below 15% spare capacity in intensive care units. Within days, areas accounting for more than three quarters of the state’s population were subject to the restrictions. The Golden State accounts for 12% of US employment, and 15% of GDP. Nonetheless, with permanent layoffs across the country stabilising at levels below those seen during the Global Financial Crisis, the arrival of vaccines should lead to renewed jobs growth through 2021.

Refresh this chart in your browser | Edit the chart in Datastream

Refresh this chart in your browser | Edit the chart in Datastream

Want more charts and analysis? Access a pre-built library of charts built by Fathom Consulting via Datastream Chartbook in Refinitiv Eikon.

The US Food & Drugs Administration was expected to issue emergency approval for the Pfizer/BioNTech vaccine within days. While the US vaccination programme is likely to prove the most important factor when thinking about the economic outlook for the coming year, fiscal support also matters. Reports pointed to a possible bipartisan Senate bill that would provide a further $908 billion in support. The bill faces an uncertain future however as the Republican Senate Leader, Mitch McConnell, continues to oppose mooted increases in aid to state and local governments. He has previously supported a package worth $500 billion. The bigger picture is that a strong Republican showing in this year’s Senate races has reduced the likelihood of significant increases in spending by the Biden administration. Nonetheless, US monetary and fiscal support this year has been greater than in peer economies, helping to explain US economic resilience in the face of a relatively lacklustre health response.

Refresh this chart in your browser | Edit the chart in Datastream

Refresh this chart in your browser | Edit the chart in Datastream

If the Republicans retain the Senate after Georgia’s two run-offs in January, the most plausible path for further fiscal support could be infrastructure spending. With the balance of power in the US upper chamber certain to be finely balanced, more centrist members on either side may be able to find common ground on a package of infrastructure measures. The US’s vaccine development programme Operation Warp Speed is admired as an impressive public-private partnership, and it is possible that some in Congress will be tempted to replicate it, with investment in advanced technology, or in research and development that is critical to national security.

Indeed, such investment could be motivated by concern about the Chinese government’s support for sectors deemed critical by the authorities in Beijing. It is worth noting however that measures of China’s high-tech exports suggest that this support has not paid off yet, and that official and international estimates of China’s high-tech exports are overstated. Nonetheless, rapid vaccine development highlights the economic benefits of investing in science – something that was perhaps overlooked in Washington DC pre-COVID.

Refresh this chart in your browser | Edit the chart in Datastream

Join a growing community of asset managers and stay up to date with the latest research from Refinitiv and partners to help you inform your investment decisions. Follow our Asset Management LinkedIn showcase page.

________________________________________________________________________________________

Refinitiv Datastream

Financial time series database which allows you to identify and examine trends, generate and test ideas and develop view points on the market.

Refinitiv offers the world’s most comprehensive historical database for numerical macroeconomic and cross-asset financial data which started in the 1950s and has grown into an indispensable resource for financial professionals. Find out more.

Article Keywords , ,

Get In Touch

Subscribe

We have updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.x